MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis

Abikhair, Melody; Roudiani, N.; Mitsui, Hiroshi; Krueger, James G.; Pavlick, Anna C.; Lee, James; Therrien, Jean-Philippe; Meehan, Shane A; Felsen, Diane; Carucci, John A.

doi:10.1016/j.jid.2016.10.036

Cited by 16 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on various cancers (such as non-small cell lung carcinoma (28), gastric cancer (29), urothelial bladder cancer (30), cutaneous squamous cell carcinoma (31) and lymphoma (32)) have shown a direct relationship between MAGE-A3 expression and poor prognosis. However, no study has been conducted to investigate the association between this marker and the prognosis of PCa.…”

Section: Discussionmentioning

confidence: 99%

Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer

Khalvandi

Abolhasani

Madjd

et al. 2020

Preprint

View full text Add to dashboard Cite

Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer- testis antigens and is common in various types of cancers. Due to its high immunogenicity and oncogenicity, it has been a candidate for cancer immunotherapy and used as a cancer vaccine in clinical trials of various types of cancers. In this study, for the first time, we performed immunohistochemical analysis to evaluate the expression of MAGE-A3 in 153 formalin-fixed paraffin-embedded prostate tissue samples including 112 cases of prostate cancer (PCa), 22 cases of benign prostatic hyperplasia (BPH) and 19 cases of high-grade prostatic intraepithelial neoplasia (HPIN). Both nuclear and cytoplasmic expressions of MAGE-A3 with different staining intensities were observed among the tissues. Increased expression of MAGE-A3 was significantly found in PCa tissues compared to both HPIN and BPH tissues (nuclear expression at P = 0.011, and cytoplasmic expression at p = 0.034; for both comparisons P < 0.0001, respectively). A significant correlation was observed between higher nuclear and cytoplasmic expressions of MAGE-A3 with Gleason score (P < 0.0001 and 0.006, respectively). Increased expression of MAGE-A3 was associated with shorter biochemical recurrence-free survival (BCR-FS) and disease-free survival (DFS) of patients (P = 0.042 and P = 0.0001, respectively). In multivariate analysis, nuclear expression of MAGE-A3 and Gleason score (≤ 7 vs > 7) were independent predictors of the DFS (both; P = 0.019). Nuclear expression of MAGE-A3 was also significantly related to BCR-FS (P = 0.015). MAGE-A3 can be considered as a valuable predictor for poor prognosis and an attractive option for vaccine immunotherapy in patients with PCa.

show abstract

Section: Discussionmentioning

confidence: 99%

Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer

Khalvandi

Abolhasani

Madjd

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Due to the variability of grades and standard, we could not present a meta-analysis on the correlation between stage and MAGEA3 expression. However, some had already presented MAGEA3 correlated with high tumor stage and poor pathological characteristics (10,31).…”

Section: Discussionmentioning

confidence: 99%

“…Multiple studies in vitro were also trying to use small molecule like microRNA to inhibit MAGEA3 to inhibit tumor progression and proliferation (6,7). In addition, a few pre-clinical studies detected high-level of MAGE-A3 promoter methylation and MAGEA3 expression correlated with elevated proliferation in vitro in gastric, pancreatic, and cutaneous squamous cell cancer (8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Detecting Melanoma Antigen Family A3 Expression in Solid/Non-Solid Human Tumor

Jiang

Han

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: MAGEA3 is a member of melanoma antigen family and has been recognized to express in many types of human cancers recently. In spite of the development of cancer vaccine, the prognostic value of MAGEA3 has not been well evaluated, due to the variability of clinical data and lack of clinical trials on the prognostic values.Method: Studies that evaluated MAGEA3 expression with a follow-up for at least 36 months were selected by searching in PubMed, WOS, Cochrane library, Embase. Published data was recorded and calculated into odds ratios (OR) for mortality in three or five years with Mantel-Haenszel random-effect model. Results: 11 studies were selected. The median positive rate was 45%. MAGEA3 always combines with worse survival on three or five years survival. The correlation between MAGEA3 and squamous carcinoma seemed stronger than adenocarcinoma on three-year OS while things got a reverse when it came to five-year OS. Most importantly, we found that all solid tumors originated from endoderm seemed to enjoy a strongest correlation among all the three germ layers.Conclusion: In this meta-analysis, we found that the expression of MAGEA3 can connect with worse outcome, and it probably can be a predictor for patients’ prognosis in clinical practice.

show abstract

“…The negative role of MAGEA3 protein has been demonstrated in previous studies, and this is consistent with our results. 10 , 25 – 29 MAGEA3 expression can significantly promote cell proliferation and tumor survival and suppress apoptosis, while silencing MAGEA3 can improve the chemotherapy sensitivity of tumor cells. 30 – 32 The role of XAGE1 remains controversial at present.…”

Section: Discussionmentioning

confidence: 99%

Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer

Shi

Cao

Grigorev

et al. 2018

CMAR

View full text Add to dashboard Cite

BackgroundCancer/testis antigen (CTA) expression was found to be highly heterogeneous in previous studies. We aimed to establish a precision CTA profiling in resected stage III non-small cell lung cancer (NSCLC) and demonstrate the best CTA combination covering the widest range of NSCLC cases.Materials and methodsThe expression of 10 CTAs was evaluated in 200 resected stage III NSCLC tissue specimens at protein level. Hierarchical clustering and python programming language analyses was used to demonstrate CTA expression and coverage.ResultsThe most commonly expressed CTAs for total cases were MAGEA1 (60.0%), MAGEA10 (50.0%), and KK-LC-1 (47.5%). CTA expression was histology dependent, and concurrent expression was common. The best 2, 3, and 4 CTA combination covered 72.0%, 76.5%, and 79.5% of total cases, respectively. Stratified analysis based on variable clinicopathological characteristics achieved the maximum coverage of 92.3% with only 2 CTA combination in patients with features of male sex, positive smoking history, and adenocarcinoma, compared with a 85.0% coverage when 10 CTAs were assessed. Selected CTA expression was correlated with prognosis based on subgroup analysis. No significant difference was found between CTA expression and epidermal growth factor receptor mutant status.ConclusionWe established an individualized CTA profiling in resected stage III NSCLC based on 10 CTA expression. With the help of computer programming language, the goal of the maximum CTA expression coverage was reached by using the least CTA combination based on sex, smoking history, and histology. These results were significant for the further study of CTA-specific T-cell immunotherapy.

show abstract

MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis

Cited by 16 publications

References 14 publications

Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer

Nuclear overexpression levels of MAGE-A3 predict poor prognosis in patients with prostate cancer

Detecting Melanoma Antigen Family A3 Expression in Solid/Non-Solid Human Tumor

Establishment of cancer/testis antigen profiling based on clinicopathological characteristics in resected pathological stage III non-small cell lung cancer

Contact Info

Product

Resources

About